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Background: Although trials have shown efﬁcacy of unprotected left main percutaneous
coronary intervention (uLMPCI), data from Indian subcontinent are lacking. Hence, we
planned this observational analysis of single-center uLMPCI data.
Objectives: To study long-term outcome after uLMPCI and identify predictors of adverse
outcome.
Methods: Case details of 62 consecutive patients of uLMPCI between 2006 and 2013 were
retrieved from a computerized database wherein detailed records were maintained.
Results: Mean follow-up duration was 669.8  404.2 days. Procedural success rate was 98.4%.
Primary endpoint was composite of major adverse cardiovascular and cerebrovascular
events (MACCE), which included cardiac death (CD), cerebrovascular accident (CVA), myo-
cardial infarction (MI), and need for repeat intervention (RI) at three years. MACCE occurred
in 13 (20.9%) patients. Cardiac death (CD), (including possible stent thrombosis), RI, and CVA
occurred in 6 (9.7%), 5 (8%), and 2 (3.2%) patients, respectively. Overall three-year MACCE-free
survival rate was 76.7%. Event-free survival rate was similar among patients who underwent
uLMPCI alone and patients who underwent uLMPCI along with additional one-vessel PCI
[(88.9% vs 81.8%), p = 0.492], while survival rate was lower in patients who underwent uLMPCI
along with PCI of additional two or more vessels (40%, p = 0.036). Patients with syntax score
≤32 had higher event-free survival rate than those with syntax score >32 [(87.1% vs 33.3%),
p = 0.001]. Syntax score >32 was the only independent predictor of adverse outcome.
Conclusion: uLMPCI is safe and effective alternative to CABG for LM alone and LM plus single-
vessel disease with syntax score ≤32.
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In patients with coronary artery disease, approximately 6%
have signiﬁcant left main (LM) disease.1 In view of the large
area of myocardium under jeopardy, LM interventions have
potential for major ischemic impediment and thus remain a
major therapeutic challenge.
In patients with high surgical risk and low-risk anatomical
features, PCI for ULMCA lesion is a class IIa indication
according to recent guidelines.2 Recent randomized controlled
trials (RCTs),3–6 registries,7–9 and meta-analysis10 have shown
feasibility and safety of DES implantation in this challenging
subset of patients and results comparable with CABG in terms
of MACCE occurrence. However, CABG still remains the
procedure of choice for treatment in patients with high-risk
anatomy.
Although several multicentric studies are available from
the western world and far east, there is insigniﬁcant data of
uLMPCI from the Indian subcontinent. Moreover, results often
vary depending on the experience of the operator in this
challenging subset of patients. Hence, we aimed to evaluate
the procedural success and long-term outcome of uLMPCI with
drug-eluting stents (DES) and identify predictors of adverse




A total of 62 consecutive patients, who underwent LMPCI
between January 2006 and December 2013, were analyzed in
this single-center registry. The decision to perform LMPCI was
made at the discretion of performing physician on the basis of
lesion characteristics, hemodynamic condition of the patient,
and patient preference. A written informed consent was
obtained prior to the procedure in all patients as per institution
protocol. All data related to the procedure, patient's clinical
presentation, and follow-up were retrieved from individual-
ized computerized database software, where all such records
were maintained with yearly follow-up information. Incom-
plete records were refreshed with telephonic contact with the
patients between December 2013 and August 2014. Patients
were risk stratiﬁed also according to syntax score.11 Approval
of the institutional ethics committee was taken for data
analysis.
2.2. Medication
All patients were pre-treated with Aspirin and loaded with
clopidogrel 600 mg. Unfractionated heparin was given at the
time of procedure and titrated to maintain ACT >280 seconds
intraprocedure. GpIIb/IIIa inhibiting agents were given at
discretion of operator in view of complexity of the lesion, stent
length, multiple stents, and patient's clinical status. Post-
procedure, all patients were prescribed clopidogrel at least for
one year and advocated aspirin for whole life. Other
cardioactive medication was prescribed in accordance withpatient's clinical need and guidelines recommendation.
Complete revascularization was aimed in all patients, except
those who presented with ACS, in whom only culprit lesion
was done at ﬁrst go and signiﬁcant nonculprit lesion was
revascularized later in a staged procedure, usually within two
weeks of index PCI.
2.3. Follow-up
All patients were followed up in cardiology outpatient
department, initially at 3 months after PCI, followed by a visit
after 6 months, and then yearly. No routine follow-up
angiography was done. However, symptomatic patient was
subjected to check angiography.
2.4. Endpoints
The primary endpoint of study was a composite of major
adverse cardiovascular and cerebrovascular events (MACCE),
which included CD, myocardial infarction (MI), stroke, and
need for RI. Secondary endpoint was composite of all the
above, and symptoms of angina in addition.
2.5. Deﬁnitions
Technical success: Technical success was deﬁned as deployment
of stent in the target lesion successfully.
Procedural success: It was deﬁned as target lesion (vessel)
revascularization with residual diameter stenosis of <10% and
TIMI 3 ﬂow without any major procedural complication or
immediate post-procedure adverse event like MI, acute stent
thrombosis, need for emergency target revascularization, or
CD.
Complete revascularization: Complete anatomic revasculari-
zation was deﬁned as treatment of all coronary artery
segments >1.5 mm in diameter with ≥50% diameter stenosis.12
Target lesion revascularization (TLR): TLR was deﬁned as
repeat intervention of target lesion up to 5 mm segment
proximal and distal to stent.
Target vessel revascularization (TVR): TVR was deﬁned as
repeat intervention of any segment of coronary vessel
proximal or distal to the target lesion, involving its branches
and/or target lesion itself.
Cardiac death (CD): Any death due to proximate cardiac
cause (e.g. MI, low-output failure, fatal arrhythmia), unwit-
nessed death and death of unknown cause, and all procedure-
related deaths, including those related to concomitant
treatment, will be classiﬁed as CD.13
Myocardial infarction (MI): MI was deﬁned as increase in CPK-
MB level of more than three times the upper limit of normal
range associated with typical chest pain and fresh ST elevation
or new onset LBBB.
Major adverse cardiovascular and cerebrovascular events
(MACCE): MACCE was deﬁned as occurrence of nonfatal MI,
CD, RI, including TLR/TVR and any new vessel revasculariza-
tion or cerebrovascular accident (CVA) during follow-up
period.
Stent thrombosis (ST): Stent thrombosis was labeled as acute,
subacute, late, and very late when event occurred within
24 hour, 30 days, <1 year, or >1 year, respectively after
Table 2 – Angiographic and procedural characteristics
among patients (n = 62).
Site of lesion
Ostial/Shaft 22 (35%)
Distal bifurcation 40 (64.5%)
(a) Preexisting LM bifurcation lesion 30/40 (48.4%)




Single stent 23 (37.1%)
Multiple stent (≥2) 39 (62.9%)
(a) Bifurcation site alone 15/39 (38.4%)
(b) Additional site 24/39 (61.5%)
Number of vessels intervened
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 3 6 – 4 238procedure. Deﬁnite, probable, and possible stent thrombosis
was deﬁned according to ARC deﬁnition.13
2.6. Statistical analysis
Statistical analysis was done using IBM SPSS Statistical
Software (IBM SPSS Statistics version 17.0, IBM SPSS, USA).
Continuous variables were expressed as mean  standard
deviation (SD) and categorical variables were expressed as
percentage. p values ≤0.05 were considered signiﬁcant.
Demographic, clinical, angiographic, and procedural variables
were tested to determine signiﬁcant ( p < 0.05) univariate
correlates of immediate and long-term poor outcomes on Cox
regression analysis. Multiple variable Cox proportional hazard
analyses were then performed, with the enter method for all
pertinent covariates. Results of multiple variable Cox analyses
are reported as hazard ratios with 95% conﬁdence intervals (CI)
and p values. Kaplan–Meier survival analysis was used to
analyse actuarial survival rates, and a log-rank test was used
to compare different survival curves. Kaplan–Meier estimates
were used to determine event-free survival (survival with
freedom from CD, MI, ST, RI, and CVA). Mean survival time was
reported.
3. Results
3.1. Basic demographic proﬁle
Baseline characteristics of study group are summarized in
Table 1. A total of 62 patients were included in the study. Mean
age of the patients was 59.5  10.3 years. Men comprised 45
(72.6%) and females constituted 17 (27.4%) of the total. A total
of 16 (25.8%) patients were diabetics. All were on oral
antidiabetic drugs and none of these patients were on insulin
therapy. HTN was present in 29 (46.8%) and 21 (33.9%) were
current smokers. Multiple-risk factors were present in 25
(40.3%) patients.
The most common clinical presentation was stable angina
in 37 (59.7%), followed by unstable angina (USA) in 16 (25.8%).Table 1 – Patients demographics.
Baseline characteristics (n = 62)





Current smoking 21 (33.9%)
Familial-risk actor 4 (6.5%)
Multiple-risk factor 25 (40.3%)
Hospital stay (days) 3.42  1.98
LVEF (in % age) 47.1  9.16
Syntax score 22.05  7.5
Clinical presentation (n = 62)
Chronic stable angina 37 (59.7%)
Unstable angina 16 (25.8%)
NSTEMI 7 (11.3%)
STEMI 2 (3.2%)Non-ST elevation myocardial infarction (NSTEMI) was diag-
nosed in 7 (11.3%) at admission and 2 (3.2%) presented with ST
elevation myocardial infarction (STEMI). The mean syntax
score was 22.05  7.5. Mean LVEF was 47.1  9.16%. A total of 12
(19.3%) patients had LV dysfunction, including moderate in 5
(7.1%) and severe in 7 (11.2%).
3.2. Procedural and angiographic characteristics
Procedural and angiographic characteristics are shown in
Table 2. Urgent PCI was done in 2 (3.2%) and 60 (96.7%)
underwent elective PCI. DES was implanted in all patients
among which 14 (22.5%) were 1st generation and 48 (77.5%)
were 2nd generation DES. Lesion location was in distal LM in 30
(48.4%), in proximal LM (ostial/LM shaft) in 22 (35.5%), and 10
(16.1%) patients had ostial LAD/LCx lesions converting into LM
bifurcation stenting intraprocedure. Among total 40 bifurca-
tion lesions, single-stent procedure was done in 25 (62.5%) and
two-stent procedure was done in 15 (37.5%) patients. Multiple
stents (≥2 stents) were used in 39 (62.9%) patients. PCI to LM
alone was done in 26 (41.9%) and multivessel PCI was done in
36 (58.1%). One additional vessel along with LMPCI was stented
in 23 (37.1%) and 2 or more additional vessels were stented in
13 (21%). Mean stent diameter and length were 3.54  0.4 mmSingle vessel (LM alone) 26 (41.9%)
Multivessel 36 (58.1%)
(a) LM + 1 additional vessel 23
(b) LM + 2 or more vessels 13
Guiding catheter size (n = 62)
6F 22 (35.5%)
7F 40 (64.5%)
Access site (n = 62)
Radial artery 30 (48.4%)
Femoral artery 32 (51.6%)





Mean stent diameter (mm) 3.54  0.4
Mean stent length (mm) 15.5  7.8
IVUS 35 (56.5%)
Kissing balloon 13 (21%)
Rotablation 2 (3.2%)
Cutting balloon 4 (6.4%)
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done in 30 (48.4%) patients and femoral artery approach in 32
(51.6%). Twenty two (73.3%) radial PCI were done with 6 F
guiding catheter and 8 (26.6%) were done with 7F guiding
catheter. All femoral procedures were done with 7F catheter.
Imaging with IVUS was used in 35 (56.5%) patients. Rotablation
was used in 2 (3.2%) patients. Complete revascularization was
done in 53 (85.5%) patients while it could not be achieved in 9
(14.5%) patients.
3.3. Procedural and in-hospital outcome
Average hospital stay was 3.42  1.98 days. Technical success
and procedural success were 100% and (61/62) 98.4%, respec-
tively. There were total of 3 (4.8%) in-hospital deaths. One
patient died immediately post-procedure while awaiting
CABG/advised for an uncontrollable leak due to LM perforation
post-stenting. One patient died in hospital due to persistent
hypotension and acute renal failure and another died due to
major gastrointestinal bleed. One patient developed delayed
pericardial effusion, which was managed with intrapericardial
glue, but later the same patient developed ischemic CVA on
fourth day of procedure but could be discharged successfully.
There was no post-procedural MI. Flow limiting dissections
occurred in 5 (8%) patients, all of which were managed with a
stent. Minor bleed in the form of arm hematoma and gum
bleed occurred in 3 (4.8%) patients.
3.4. Follow-up clinical outcome
Mean follow-up duration was 669.8  404.2 days. Follow-up
was terminated at the ﬁrst occurrence of a MACCE (CD, MI,
CVA, RI), and asymptomatic patients were followed up to 3
years.
Event details are summarised in Table 3.
3.5. 30-day outcome
At the end of 30-day follow-up, the incidence of CD was 3 (4.8%)
only (all in-hospital). There was no fresh CVA. One patient
developed ISR during index hospitalization itself and under-
went CABG. Total event rate at 30 days was 5 (8%).
3.6. Long-term clinical outcomes
1-Year outcome: At 1 year, there were a total of 5 (8%) CDs, with
two new deaths occurring between 30 days and 1 year,Table 3 – Events details of MACCE over 3 years (cumula-
tive).
Events In-hospital 30 days 1 year 3 years
CD 3 (4.8%) 3 (4.8%) 5 (8%) 6 (9.7%)
CVA 1 (1.6%) 1 (1.6%) 2 (3.2%) 2 (3.2%)
Repeat Intervention 1 (1.6%) 1 (1.6%) 4 (6.4%) 5 (8%)
Total MACCE 5 (8%) 5 (8%) 11 (17.7%) 13 (20.9%)
CD, cardiac death; CVA, cerebrovascular accident; MACCE, major
adverse cerebrovascular and cardiovascular events.including a sudden CD after 45 days in one and similar death
after 6 months of procedure in another patient. A total of three
more patients developed angiographic restenosis and needed
RI during this period. Of the total of four patients with need for
RI, 2 (3.2%) underwent CABG and another 2 (3.2%) patients
underwent repeat PTCA. One (1.6%) patient developed a fatal
CVA after 8 months of procedure. Total event rate at 1 year was
11 (17.7%).
3-Year outcome: At the end of 3 years, the incidence of total
CD was 6 (9.7%), which includes 1 death due to possible stent
thrombosis at 485 days after procedure. Another patient
needed RI after 2 years due to new lesion in another vessel
with repeat PCI. RI was needed in a total of 5 (8%) patients. Four
(6.4%) presented with in-stent restenosis (ISR) and one had
disease in new vessel. Two of these (3.2%) underwent CABG
and 3 (4.8%) were revascularized with repeat PTCA.
Table 3 shows the details of combined MACCE. A cumula-
tive MACCE rate was 13/62 (20.9%) at the end of 3 years. At end
of follow-up period, the incidence of CD (including three
possible stent thrombosis), need for RI, and CVA were 6 (9.7%),
5 (8%), and 2 (3.2%), respectively (Fig. 1).
3.7. Predictors of adverse outcome (MACCE)
Predictors of MACCE using univariate and multivariate
analyses have been shown in Table 4. Higher syntax score
>32 [HR = 11.5 (95% CI 3.7–35.7), p = 0.001], multivessel stenting
[HR = 2.3 (95% CI 1.1–4.65), p = 0.027], and use of multiple stent
[HR = 1.9 (95% CI 1.1–3.2), p = 0.016] were signiﬁcant factors
predicting MACCE on univariate analysis while on multivari-
ate analysis higher syntax score (>32) [HR = 9.3 (95% CI 2.8–
30.2), p = 0.001] was found to be the only independent predictor
of adverse outcome. Although there was a trend toward poorer
outcome in diabetic patients on univariate analysis [HR = 2.6
(95% CI 0.9–7.8), p = 0.084], it was not statistically signiﬁcant.
3.8. Secondary outcome
It is composite of CD, MI, CVA, and recurrent angina after
procedure. A total of 11 (17.7%) patients presented with
recurrent post-PTCA angina. All patients with recurrent
angina were subjected to repeat angiography and otherFig. 1 – 3-Year clinical outcome in RI need for repeat
intervention, CVA, cerebrovascular accident; MACCE, major
adverse cerebrovascular and cardiovascular events.
Table 4 – Univariate and multivariate predictors of
adverse outcome.
Variable Univariate Multivariate
HR (95% CI) p value HR (95% CI) p value
Syntax
score
11.5 (3.7–35.8) 0.001 9.3 (2.8–30.2) 0.001
Multiple
stent
1.9 (1.1–3.2) 0.016 1.2 (04–4.0) 0.728
Multiple
vessels
2.25 (1.1–4.6) 0.027 1.36 (0.3–6.3) 0.698
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in-lesion/in-segment restenosis or a signiﬁcant new vessel
disease. The other 6 (9.7%) patients were found to have no ISR
or new disease on repeat angiography. One patient was found
to be severely anemic while the rest 5 (8%) patients had
treatment optimized and were asymptomatic on optimal
medical therapy on further follow-up.
3.9. Event-free survival
Mean event-free survival was 2.46 years (2.2–2.7). Actuarial
survival rate free of MACCE was 82.3%, 80%, and 76.7% at 1
year, 2 years, and 3 years, respectively (Fig. 2).
3.10. Predictors of MACCE
(1) Syntax score ≤32 vs syntax score >32 (Fig. 3): Patients with
syntax score ≤32 had higher mean event-free survival [2.8
years (95% CI 2.6–3.0)] compared to patients with syntax
score >32 [1.1 years (95% CI 0.4–1.9), p < 0.0001]. Patients
with lower score (≤32) had event-free survival rate of 87.1%
at 3 years as compared to 3-year event-free survival rate of
33.3% in patients with syntax score ≥32 ( p < 0.0001) (Fig. 3).
(2) Diabetics vs non-diabetic patients (Fig. 4): Non-diabetic
patients had a mean event-free survival comparable with
diabetic patients [2.6 years (95% CI 2.34–2.9) vs 2.0 years
(95% CI 1.4–2.6), p = 0.073]. In non-diabetic patients, 3-year
event-free survival rate was 81% while in diabetic patients
the respective survival rate was 62.5%, which was not
statistically different ( p value = 0.073).Fig. 2 – Kaplan–Meier estimates of Event-fr(3) LM alone PCI vs LM plus additional vessels PCI: Fig. 5 shows
Kaplan–Meier curve of event-free survival in accordance
with the different number of vessels intervened along with
uLMPCI. Patients with PCI of LM alone had mean event-free
survival of 2.7 years (95% CI 2.3–3.0), which is comparable to
mean event-free survival in patients who underwent PCI of
LM and additional one vessel PCI [2.5 years (95% CI 2.1–2.9),
p = 0.492] while patients with LMPCI with additional 2 or
more vessel PCI had lower mean event-free survival [1.9
years (95% CI 1.2–2.6), p = 0.036]. Patients with LMPCI alone
had a 3-year event-free survival rate comparable to those
who underwent PCI of additional one vessel (88.9% vs
88.1%, p = 0.569), which is superior to 3-year event-free
survival rate of 40% ( p = 0.036) in patients who underwent
LMPCI along with additional 2 or more vessels PCI.
4. Discussion
The present study is a single-center experience of ULMCA PCI
with drug-eluting stent (DES) from the Indian subcontinent.
There was high technical success and procedural success rate
with three in-hospital deaths. The main ﬁnding of this study is
that uLMPCI is safe and effective treatment alternative to
CABG in low- to moderate-risk anatomy patients (syntax score
<32). Patients' selection was done at the discretion of the
primary operator having discussed the pros and cons in
individual cases with the patients and in-house cardiac
surgeon and according to patient preference for PCI relative
to surgery.
4.1. In-hospital result and procedural complication
The procedural success rate was 98.4% in this study including
patients who presented with acute coronary syndrome, which
is comparable to other reports.7 Higher complete revasculari-
zation (85.5%) was achieved in our patients as compared to
other studies.3,4,14 Average hospital stay (3.42  1.98 days) was
also short in our study in comparison to PCI arm of other
studies,4 which may be attributed to higher rate of transradial
procedure. At our center at least 50% of these LMPCI were doneee survival in whole study population
Fig. 3 – Kaplan–Meier estimates of Event-free survival in patient subgroups divided according to syntax score
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was attributable to procedural complication. All of these three
patients had high-risk anatomy with syntax score of ≥32 and
two were elderly (age ≥75 years), although one of them died of
major GI bleed unrelated to these characteristics. No post-
procedural myocardial infarction was documented. Post-
procedure, there were three minor bleeds in the form of
arm hematoma and a minor gum bleed, which were managed
conservatively without any need for blood transfusion. Again
radial site of access might contribute to lower rate of major
bleeding complication.
4.2. 30-day outcome
Our series has overall MACCE rate of 5 (8%) at 30 days, which is
slightly higher than PCI arm of LEMANS Study3 (4.8%) and as
reported in PCI arm (4%) of study by Boudriot et al.5 This may be
due to the fact that these RCTs had excluded highest risk
patients and ours was a all-comers design. DELFT registry7 has
higher (11.4%) event rate at 30 days as patients with emergent
PCI had higher adverse events in that study. Although our
study also included ACS patients but no emergent PCI was
done and none of our patient were in cardiogenic shock. Only 2Fig. 4 – Kaplan–Meier estimates of Event-free survival in
Diabetics vs non-diabetics(3.2%) patients were of acute ST elevation MI in ACS group and
all were in Killip class I
4.3. 1-Year and 3-year clinical outcome
The one-year incidence of MACCE in our patients was 17.7%,
which is comparable to PCI arm of SYNTAX trial4 and the study
by Buodriot et al.5 and lower than DELFT7 registry and other
studies.15 The 3-year rate of overall MACCE was 20.9% in our
study, which was lower than other reported MACCE rates in
some studies.4,7–9 The higher event rates in these multicentric
studies could be driven by multiple operators with varying
levels of expertise giving varied acute outcomes while ours
was a single-center experience with largely a single-primary
operator with procedural technique very much reproducible
and a level of expertise, which may also be rather good if not
best, which is bound to play a role in outcome of these cases,
and which form a challenging subset within all PCIs. Further,
higher event rate in these studies might also be explained by
higher lesion complexity as compared to our population
because our mean syntax score (22.05  7.5) was lesser. MeanFig. 5 – Kaplan–Meier estimates of Event-free survival in
patients with different groups according to number of
vessels involved
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29.6  13.5 and 23.5, respectively.
Our study showed a three-year actuarial event-free survival
rate of 76.7%, which is comparable to PCI arm of DELTA
registry,7 study by Lee et al.,16 and the MAIN COMPARE study,9
but higher than DELFT7 registry (73.5%). A lower rate of RI may
contribute to higher event-free survival rate in our study as
compared to other reports. Again a fact that may be
contributing to the better results might be a good case
selection with lower mean syntax score. As such the syntax
score stood as an independent predictor of adverse event on
multivariate analysis in our study results. Moreover, all other
data are from European or far eastern population and our
study involves only the Indian population. There may be a
racial and ethnic difference in tendency toward restenotic and
thrombotic complications.
4.4. Comparison with CABG
Although evidence from recent RCTs has shown that uLMPCI
may provide at least equivalent results to CABG in less complex
anatomy, practice guidelines still consider CABG as class I
indication. In these studies, MACCE rate was higher in PCI arm
as compared to CABG mainly due to a higher need for RI. In our
study, RI rate was signiﬁcantly lower than reported previously.
Although overall three-year mean event-free survival was lower
than that reported for CABG, it is similar (86%) to CABG17 in a
patient with syntax score ≤32. Therefore although our sample
size is small, it shows a similar efﬁcacy to CABG in low to
intermediate complex anatomy and the results do reﬂect what
best could be achieved in left main intervention.
5. Limitation
We do feel that our study has few limitations. First, it is a single-
center experience with largely a single-primary operator, and
second, there could be a selection bias in patient population.
Third, it is an observational analysis with total number of
patients being small, and lastly, the study group was heteroge-
neous with all types of LM patients being included.
5.1. Conclusion
We conclude that uLMPCI is safe and effective treatment
alternative to CABG in selected LM alone and LM plus single-
vessel disease patients with syntax score ≤32.
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